key: cord-0707146-pdkm9atu
authors: Shook, LL; Collier, AY; Goldfarb, IT; Diouf, K; Akinwunmi, BO; Young, N; Brown, A; Hacker, MR; Kaimal, AJ MD; Gray, KJ; Edlow, AG
title: Vertical transmission of SARS-CoV-2: consider the denominator
date: 2021-04-29
journal: Am J Obstet Gynecol MFM
DOI: 10.1016/j.ajogmf.2021.100386
sha: b1195e26c09aeb9bbd321605e7fa20dd22167913
doc_id: 707146
cord_uid: pdkm9atu

nan

More than 82,000 pregnant women in the United States have tested positive for SARS-CoV-2. 1 Published estimates of the incidence of vertical transmission-the passage of SARS-CoV-2 from mother to baby during pregnancy or childbirth-range from 1-3%, but these reports may be limited in their methodology. [2] [3] [4] The largest systematic review and meta-analysis to date reports a pooled estimate of 3.2%, 2 yet includes data from cohort studies and case series published early in the pandemic, when reports on outcomes of SARS-CoV-2 positive newborns were urgently needed to guide clinical management and potentially overrepresented. Here we provide additional data on vertical transmission from a multi-center cohort of pregnant women with SARS-CoV-2 infection.

Women with a positive nasopharyngeal PCR for SARS-CoV-2 during pregnancy who 

We identified no cases of vertical transmission in our cohort, which includes a large proportion of women with asymptomatic or mild disease. Newborns were tested in accordance with hospital infection control policies (e.g. not tested if born to convalescent mothers). While vertical transmission does occur, data from our centers suggest the incidence of SARS-CoV-2 vertical transmission, as detected by neonatal nasopharyngeal swab, is likely lower than the 1-3% estimated in previous reports. [2] [3] [4] The challenge in selecting the denominator for calculating the incidence of vertical transmission is illustrated by the CDC report on 2,869 newborns of women with SARS-CoV-2 infection during pregnancy. 4 Test results were available on 610 newborns-only 21% of the cohort-of which 16 (2.6%) tested positive. More than 60% of newborns without testing information were delivered greater than 10 days from maternal infection. These newborns were either not tested or had a negative result which, unlike a positive result, is not mandated to be reported to the state. If all newborns born to women with SARS-CoV-2 infection in pregnancy were included in the denominator, the incidence of identified vertical transmission would be 0.6% (16 of 2,869) , not 2.6%.

Consensus on how to define, detect, and report vertical transmission of SARS-CoV-2 is lacking. Although both the AAP and CDC recommend testing all infants born to mothers with active SARS-CoV-2 infection at the time of delivery, the optimal strategy for evaluating vertical transmission in the setting of early (first and second trimester) pregnancy infections is not known. Although nasopharyngeal PCR-based testing of infants born to convalescent women is likely to be low yield, sampling the fetal compartment during maternal SARS-CoV-2 infection to assess for transmission could incur risk without clear benefit. Estimates of the incidence of vertical transmission that exclude untested newborns should be interpreted with caution, as untested newborns cannot demonstrate their presumed SARS-CoV-2 negative status. We assert that the appropriate denominator to estimate the incidence of vertical transmission includes all newborns of women infected with SARS-CoV-2 during pregnancy. 

COVID-19 Cases, Deaths, and Trends in the US

Vertical transmission of coronavirus disease 2019: a systematic review and meta-analysis

Infant Outcomes Following Maternal Infection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): First Report From the Pregnancy Coronavirus Outcomes Registry (PRIORITY) Study

Birth and Infant Outcomes Following Laboratory-Confirmed SARS-CoV-2 Infection in Pregnancy -SET-NET, 16 Jurisdictions

FAQs: Management of Infants Born to Mothers with Suspected or Confirmed COVID-19